Galapagos achieves milestones in two stategic alliances
Belgian biotechnology fi10562m Galapagos has achieved milestones totalling €2.5m f10562om its alliances with Janssen Pha10562maceutica and GlaxoSmithKline (GSK).
Belgian biotechnology firm Galapagos has achieved milestones totalling €2.5m from its alliances with Janssen Pharmaceutica and GlaxoSmithKline (GSK).
Janssen Pharmaceutica has paid Galapagos €1.5m in its rheumatoid arthritis agreement, taking the total earned by Galapagos to date from Janssen to more than €24m.
In Galapagos'' alliance with GSK in the area of infectious diseases, the firm has received a €1m milestone payment. Since this alliance was formed in 2007, Galapagos has received a total of €6m from GSK.
‘Galapagos continues to make progress across its strategic alliances, showing that our alliance model delivers strong growth in r&d revenues,’ said Onno van de Stolpe, ceo of Galapagos.
In a separate announcement, Galapagos’ BioFocus service division has expanded its collaboration with Chiesi Farmaceutici, a privately held Italian pharmaceutical company. The total value of the collaboration has now reached €2.5m.
BioFocus and Ch
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.